Board of Directors
Pacific Therapeutics Ltd. is a publicly traded company listed on the Canadian National Stock Exchange (CNSX) under the symbol PT.
Pacific Therapeutics a Specialty Pharmaceutical Company is focused on the identification, development and sales of drug candidates to treat diseases of the liver and lungs caused by excessive and progressive tissue scarring, called fibrosis.
The company's strategy includes the reformulation and repurposing of FDA approved drugs to treat excessive scarring in liver and lung disease. Pacific Therapeutics will complete clinical testing, manufacturing and other regulatory requirements sufficient to seek marketing and sales authorizations of its drug candidates in the US, Europe, Canada and other countries.
Pacific Therapeutics' lead drug candidate; PTL-202 is set for Phase 1 clinical trials in 2012. PTL-202 is a combination of drugs that have been approved by the FDA to treat diseases other than fibrosis. PTL-202 is being developed by Pacific Therapeutics to treat a progressive lung scarring disease, named Idiopathic Pulmonary Fibrosis (IPF). More people die of annually IPF than either prostate or breast cancer. IPF is estimated to be a $2 billion market opportunity.
On July 12, 2011 Pacific Therapeutics engaged CRBIO (Clinical Research and Biosciences of Hyderabad), India to conduct a clinical trialwith PTL-202 in a drug to drug interaction study in humans. CRBIO is the clinical trials a division of RA Chem Pharma Limited, India.
Pacific Therapeutics' second drug candidate, PTL-303, is also a combination of drugs, one of which has been approved for human use in Japan. PTL-303 has been shown to be effective in the reduction of molecules that contribute to the development of diseases including, liver cirrhosis in humans. PTL-303 may be developed as a treatment to reduce the severity of progressive diseases like chronic liver disease.
Chronic liver disease which may lead to cirrhosis of the liver is responsible for over 1.4m deaths annually (WHO, World Health Report 2004) In the US chronic liver disease is among the top ten disease related causes of death (CDC, National Center for Health Statistics, 2004). This market is estimated to be $3.0 billion.
A provisional patent covering PTL-202 titled: "Composition and Method for Treating Fibrosis" was filed by the company with the United States patent office on October 29, 2008. A PCT application covering the technology of PTL-303 was filed October, 2009.
Pacific Therapeutics' business and drug development strategy reduces risk, time and the capital costs of developing new drug therapies for liver and lung diseases caused by fibrosis. By combining existing approved drugs that have already known safety and toxicity profiles, the company eliminates the inherent risks involved with basic pre clinical research and animal testing.
Future Plans - 2012
- Approval for Phase 1 Clinical Trials PTL-202 for drug-drug interaction as required for regulatory approval
- Initiate Phase 1 drug-drug interaction Clinical Trials PTL-202
- Results from 1 drug-drug interaction Clinical Trials PTL-202
- Manufacturing and Bioavailability studies
- Prepare for 2013 Health Canada Regulatory Approval for PTL-202
